港股異動 | 開拓藥業-B(9939.HK)拉昇漲6% 年內累計漲幅高達240%
格隆匯4月15日丨開拓藥業-B(9939.HK)午後拉昇轉漲,現漲幅擴大至5.89%,報35.95港元,暫成交7990萬港元,總市值133億港元。該股今年迄今已錄得高達240%的漲幅,曾創下38.65港元的歷史高價。
華創證券此前給予公司38.5港元的目標價,首次覆蓋,給予“強推”評級。該行指出公司管線豐富,競爭格局良好,AR領域多點開花,新冠/脱髮/痤瘡適應症有望帶來百億銷售潛力。
預計未來半年開拓藥業有望迎來以下重磅催化劑:普克魯胺一線mCRPC 的rPFS 數據以及報產;普克魯胺末線mCRPC 的OS 數據,以決定是否報產;福瑞他恩治療雄激素脱髮的II 期數據;福瑞他恩痤瘡適應症完成入組;普克魯胺美國新冠輕症、重症數據,以及潛在的海外合作和銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.